WAY 120491

RN given refers to the (3S-trans)-isomer; RN for cpd without isomeric designation not available 3/91

Also Known As:

2-(3,4-dihydro-3-hydroxy-2,2-dimethyl-6-(trifluoromethoxy)-2H-1-benzopyran-4-yl)-2,3-dihydro-1H-isoindol-1-one; WAY 120491, (trans)-isomer; WAY-120,491; WAY-120491; celikalim

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrans: 130
    - Benzopyrans: 195
      - WAY 120491: 3
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - WAY 120491: 3
    - Benzopyrans: 195
      - WAY 120491: 3

Experts

1.	Cameron, N E: 1 article (06/2000)
2.	Cotter, M A: 1 article (06/2000)
3.	Hohman, T C: 1 article (06/2000)

Related Diseases

1.	Thrombosis (Thrombus) 06/01/1994 - "Celikalim inhibited white thrombus formation at i.v. doses of 0.25 mg/kg (46% inhibition) but not 0.1 mg/kg; (14.6%); equihypotensive doses of pinacidil (0.5 mg/kg; 21.7%) and cromakalim (0.2 mg/kg, 7.5%; 0.4 mg/kg, 33%) were less effective. " 06/01/1994 - "Analysis of the potassium channel openers celikalim, pinacidil and cromakalim in platelet models of thrombosis."
2.	Myocardial Infarction 01/01/1992 - "The cardioprotective effects of the K channel activator drugs celikalim (WAY-120,491) and cromakalim were studied in a canine model of myocardial infarction consisting of 90 min of ischemia and 5 h of reperfusion. " 01/01/1992 - "Potassium channel activators cromakalim and celikalim (WAY-120,491) fail to decrease myocardial infarct size in the anesthetized canine."
3.	Ischemia 01/01/1992 - "The cardioprotective effects of the K channel activator drugs celikalim (WAY-120,491) and cromakalim were studied in a canine model of myocardial infarction consisting of 90 min of ischemia and 5 h of reperfusion. "
4.	Infarction (Infarctions) 01/01/1992 - "Anatomic infarct size was 32.8 +/- 7.1% for vehicle animals (n = 5) and 32.6 +/- 13.3 and 30.9 +/- 9.8% for cromakalim- (n = 6) and celikalim-treated (n = 5) animals, respectively. " 01/01/1992 - "Infarct size (percent of risk area) was 27.7 +/- 5.6% in vehicle control animals (n = 5), 40.3 +/- 6.2% for cromakalim (n = 5) and 55.7 +/- 6.4% (p less than 0.05 vs. vehicle) for celikalim-treated animals (n = 5). "
5.	Experimental Diabetes Mellitus 06/02/2000 - "Therefore, we examined the effects of 2 weeks treatment with the K(ATP) channel openers, celikalim and WAY135201 (R-4-[3, 4-dioxo-2-(1, 2, 2-trimethyl-propylamino)-cyclobut-1-1-enylamino]-3-methoxy-+ ++benzonitri le), on sciatic nerve blood flow, conduction velocity, Na(+)-K(+) ATPase activity and glutathione content after 6 weeks of untreated streptozotocin-diabetes in rats. "

Related Drugs and Biologics

1.	Cromakalim (Levcromakalim)
2.	Potassium Channels (Potassium Channel)
3.	Pinacidil (Pindac)
4.	Glutathione (Reduced Glutathione)
5.	Adenosine Triphosphate (ATP)
6.	Adenosine Triphosphatases (ATPase)
7.	WAY135201